(VMD) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Viemed Healthcare Inc. (NYSE: VMD), focusing on liquidity and institutional trading tactics. It outlines near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis. The report highlights elevated downside risk and encourages users to sign in for full access to real-time signals and personalized analysis.
Viemed Healthcare, Inc. $VMD Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 158,762 shares of Viemed Healthcare (NASDAQ:VMD) in the second quarter, a stake valued at approximately $1.81 million, now holding 0.42% of the company. Viemed Healthcare's recent quarterly earnings of $0.07 per share missed the consensus estimate, though revenue was in line with expectations. Institutional investors collectively own 74.24% of the company, and analysts currently have a "Hold" rating on the stock with an average price target of $14.00.
Viemed Healthcare Announces Completion of Share Repurchase Program
Viemed Healthcare, Inc. announced the completion of its share repurchase program, buying back 1,976,441 common shares for approximately $13.2 million at a weighted average price of $6.69 per share. The company's CEO, Casey Hoyt, stated that this reflects confidence in Viemed's long-term outlook and commitment to enhancing shareholder value, supported by a strong balance sheet and increasing free cash flow. Viemed plans to continue investing in growth opportunities and returning capital to shareholders.
Viemed Healthcare shifts to diversified home healthcare, boosting growth and cash flow.
Viemed Healthcare (VMD) is transitioning from a respiratory equipment provider to a diversified home healthcare company, expanding into sleep, resupply, and women's health. This strategic shift is driving strong revenue growth and improving free cash flow, despite some margin pressure. Analysts rate VMD as a Strong Buy due to its growth potential, flexible capital allocation, and a strong margin of safety in its valuation.
Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Viemed Healthcare, Inc. announced that its President, Michael Moore, has adopted an automatic securities disposition plan (ASDP) for up to 246,000 common shares. This plan, established in compliance with securities laws and Viemed's policies, allows for pre-arranged stock sales without insider discretion, commencing as early as December 24, 2026, over approximately one year. The shares represent less than 11% of Mr. Moore's beneficially owned common shares.
Viemed Healthcare, Inc. (VMD) President Sets 10b5-1 Plan to Sell Up to 246K Shares
Viemed Healthcare, Inc. (VMD) President Michael Moore has adopted a Rule 10b5-1 plan to sell up to 246,000 shares over approximately one year, ending November 30, 2027. Sales may commence as early as December 24, 2026, and are subject to a minimum floor price. This plan represents less than 11% of Moore's total holdings and is a standard insider selling framework.
An officer owns 5.9% of Viemed Healthcare (VMD); an LLC holding his shares has a sale plan.
Viemed Healthcare officer Michael Moore, through his LLC, Moore Faster LLC, has entered into a Rule 10b5-1 trading plan to sell up to 246,000 common shares. Moore beneficially owns 2,294,018 common shares, representing 5.9% of the company, with sales under the plan scheduled to begin no earlier than December 24, 2026, and end by November 30, 2027. This plan is designed to comply with SEC guidelines for insiders to sell shares without being in possession of material non-public information.
Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Viemed Healthcare, Inc. (NASDAQ:VMD) announced that its President, Michael Moore, has adopted an automatic securities disposition plan (ASDP) to sell up to 246,000 common shares over approximately one year, ending November 30, 2027. The plan was established in compliance with U.S. and Canadian securities laws and Viemed's internal policies, at a time when Mr. Moore was not in possession of any material non-public information. These shares represent less than 11% of Mr. Moore's beneficially owned shares, and sales may begin as early as December 24, 2026, subject to a minimum floor price.
Viemed Healthcare stock holds steady as investors await next earnings update
Viemed Healthcare stock is holding steady on the Nasdaq as investors anticipate its next earnings update. The company, which specializes in home-based respiratory care, recently reported continued revenue growth and solid profitability in its latest fiscal quarter. Its business model benefits from an aging population and a shift towards home-based treatment, effectively navigating reimbursement dynamics.
Why (VMD) Price Action Is Critical for Tactical Trading
This article analyzes Viemed Healthcare Inc. (NYSE: VMD), noting weak near-term sentiment despite potential long-term strength. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide tactical trading decisions. The analysis highlights support and resistance levels across different time horizons.
VMD 8-K Filings - Viemed Healthcare, Inc. SEC 8-K
This article compiles the recent 8-K filings for Viemed Healthcare, Inc. (VMD), detailing significant events, financial results, and corporate actions. Key highlights include strong revenue growth, raised guidance for 2026, shareholder approvals for director elections and incentive plans, and share repurchase programs. The filings also cover an acquisition and credit agreement amendments, providing investors with a comprehensive overview of the company's recent performance and strategic moves.
The Technical Signals Behind (VMD) That Institutions Follow
This article analyzes Viemed Healthcare Inc. (NYSE: VMD) using AI models to identify institutional trading signals. It highlights weak near and mid-term sentiment, potentially challenging a positive long-term outlook, and outlines specific position, momentum breakout, and risk hedging trading strategies. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for VMD.
BlackRock Inc. Invests $54.59 Million in Viemed Healthcare, Inc. $VMD
BlackRock Inc. has acquired a significant new stake of 4.79 million shares in Viemed Healthcare, Inc. valued at approximately $54.6 million, giving them a 12.57% ownership. This comes as other institutional investors have also adjusted their holdings in the company. Despite the substantial institutional interest, Viemed Healthcare's recent earnings missed analyst consensus, and the stock currently holds an average "Hold" rating from analysts with a consensus target price of $14.00.
Nantahala Capital Management LLC Makes New Investment in Viemed Healthcare, Inc. $VMD
Nantahala Capital Management LLC has made a new investment in Viemed Healthcare, Inc. (NASDAQ:VMD), acquiring 632,445 shares valued at approximately $7.2 million, which represents a 1.66% stake in the company. Institutional investors and hedge funds now collectively own 74.24% of Viemed Healthcare. The company has received mixed analyst ratings, with an overall "Hold" consensus and an average price target of $14.
Raffles Associates LP Acquires Shares of 403,691 Viemed Healthcare, Inc. $VMD
Raffles Associates LP has acquired 403,691 shares of Viemed Healthcare, Inc. (NASDAQ:VMD) for approximately $4.6 million, making it their ninth-largest holding. This purchase gives Raffles Associates LP a 1.06% stake in Viemed Healthcare, while institutional investors collectively own 74.24% of the company. The article also notes recent insider sales and analyst ratings, with Viemed Healthcare currently holding an average "Hold" rating and a $14.00 price target.
533,466 Shares in Viemed Healthcare, Inc. $VMD Bought by Punch & Associates Investment Management Inc.
Punch & Associates Investment Management Inc. recently acquired 533,466 shares of Viemed Healthcare, Inc. (VMD) worth approximately $6.1 million, giving them a 1.40% stake in the company. Despite this institutional buying, analyst sentiment for Viemed Healthcare has weakened, leading to several downgrades to "Hold" and a consensus price target of $14.00. The company's recent earnings report showed revenue in line with estimates but missed EPS forecasts, and insiders have recently sold a combined 30,000 shares.
403,691 Shares in Viemed Healthcare, Inc. $VMD Purchased by Raffles Associates LP
Raffles Associates LP recently acquired 403,691 shares of Viemed Healthcare, Inc. (NASDAQ:VMD) worth approximately $4.6 million, making it their eighth-largest holding and giving them a 1.06% stake in the company. Institutional investors and hedge funds collectively own 74.24% of VMD. Analyst sentiment is mixed, with some downgrades to "Hold" ratings, while the company reported Q2 EPS of $0.07, missing estimates, but revenue slightly exceeded forecasts.
Expect Equity LLC Purchases New Holdings in Viemed Healthcare, Inc. $VMD
Expect Equity LLC has acquired a new position in Viemed Healthcare, Inc. (NASDAQ:VMD), purchasing 212,721 shares valued at approximately $2.43 million, making it their 27th largest holding. Other institutional investors have also recently adjusted their stakes in Viemed Healthcare, with various firms initiating new positions. The article also details recent trading activity, financial performance, and analyst ratings for Viemed Healthcare.
VIEMED HEALTHCARE INC : BARRINGTON RESEARCH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $14
Barrington Research has initiated coverage on VIEMED HEALTHCARE INC (VMD.O) with an "Outperform" rating, setting a target price of $14. The article briefly notes this analyst action.
Viemed Healthcare (NASDAQ:VMD) Now Covered by Barrington Research
Barrington Research initiated coverage on Viemed Healthcare (NASDAQ:VMD) with an "outperform" rating and a $14 price target, suggesting a 58% upside. This new bullish stance contrasts with MarketBeat's current "Hold" consensus among analysts. The company recently reported quarterly revenue of $78.1 million, slightly above estimates, but missed earnings per share expectations.
Viemed Healthcare, Inc. (VMD) Q1 Earnings Miss Estimates
Viemed Healthcare, Inc. (VMD) reported Q1 earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09. Despite the earnings miss, the company's revenues of $75.41 million surpassed estimates and showed an increase from the prior year. The stock has outperformed the S&P 500 year-to-date, but current analyst sentiment, based on estimate revisions, places it at a Zacks Rank #4 (Sell).
VMD | Viemed Healthcare, Inc. Common Financials - Revenue Breakdown
This page provides a financial overview of Viemed Healthcare, Inc. (VMD), focusing on its revenue breakdown, but notes a lack of specific data for revenue by segment or geography. It also offers various other financial metrics, such as insider trading, institutional holdings, analyst ratings, and corporate lobbying information. The company is described as a provider of home medical equipment and post-acute healthcare services, primarily generating revenue from medical equipment rental, sales, and supply.
Martin & Co. Inc. TN Purchases Shares of 340,771 Viemed Healthcare, Inc. $VMD
Martin & Co. Inc. TN has acquired a new stake of 340,771 shares in Viemed Healthcare, Inc. (NASDAQ:VMD) during the second quarter, valued at approximately $3.9 million. This purchase gives the firm a 0.89% ownership, adding to the 74.24% institutional ownership in the company, with other major institutional investors like BlackRock also increasing their holdings. Despite beating revenue estimates, Viemed Healthcare missed EPS expectations, and several analysts have downgraded the stock to a "Hold" rating, while two insiders recently sold a combined 30,000 shares.
Viemed Healthcare Number of Employees 2026 | Employee Count & Headcount Data
Viemed Healthcare (NASDAQ: VMD) has approximately 1,378 employees as of March 2026, marking a 21.3% growth since 2023. The company is actively hiring, with 462 job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is negative but improving, with an average salary of $68,783.
ETFs Investing in Viemed Healthcare, Inc. Stocks
This article lists various ETFs that include Viemed Healthcare, Inc. (VIJ) stocks in their holdings. It provides a detailed table with each ETF's market value, weight of VIJ, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information aims to help investors identify funds offering exposure to Viemed Healthcare, Inc. with diversified investment opportunities.
Bard Associates Inc. Makes New $3.87 Million Investment in Viemed Healthcare, Inc. $VMD
Bard Associates Inc. has made a new investment of approximately $3.87 million in Viemed Healthcare, Inc. (NASDAQ:VMD) by acquiring 339,672 shares. This makes Bard Associates Inc. an owner of 0.89% of Viemed Healthcare's stock. The article also details other institutional investments, recent analyst ratings which generally recommend "Hold," and insider selling activities by William Frazier and Timothy Smokoff.
Tocqueville Asset Management L.P. Purchases New Shares in Viemed Healthcare, Inc. $VMD
Tocqueville Asset Management L.P. recently acquired a new stake of 342,100 shares in Viemed Healthcare, Inc. (NASDAQ:VMD) during the second quarter, valued at approximately $3.9 million. Other institutional investors like BlackRock Inc., Wasatch Advisors LP, and Goldman Sachs Group Inc. also hold significant positions in the company. Viemed Healthcare currently has a "Hold" rating from analysts, with a market capitalization of $326.43 million and a P/E ratio of 23.81.
Viemed Healthcare (VMD) maps 2026 growth after 21% revenue jump
Viemed Healthcare (VMD) reported strong financial results for 2025 with net revenue up 21% year-over-year to $270 million and provided 2026 guidance projecting net revenue between $314 million and $320 million. The company highlights its growing home-based clinical care platform, diversified service lines including ventilation, sleep, and women's health, and a capital-light operating model that supports organic growth, strategic M&A, and shareholder returns. VMD also emphasized its pristine balance sheet with no net debt and significant credit facility availability to fuel future expansion.
VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance
VieMed Healthcare reported record financial results for 2025, with $270.3M in net revenue and $61.4M in Adjusted EBITDA. The company also provided 2026 guidance, projecting net revenue between $314M and $320M, and announced a new share repurchase program. These details were shared in an investor presentation highlighting growth, strong cash generation, and strategic expansion plans.
Viemed Healthcare (NASDAQ: VMD) grants new RSUs and phantom units to director
Viemed Healthcare director Sabrina Heltz reported equity-compensation transactions, including the vesting of 15,029 Restricted Stock Units and 3,757 Phantom Share Units on August 19, 2026. Simultaneously, she received new awards of 12,174 RSUs and 3,043 Phantom Share Units on August 17, 2026, which are scheduled to vest on the first anniversary of the grant date. The phantom shares that vested on August 19 were settled for cash at $8.94 per share.
Viemed Healthcare (VMD) director settles awards, sells 4.2K shares
Viemed Healthcare director Randy E. Dobbs reported the vesting and settlement of 16,763 Restricted Stock Units and 4,191 Phantom Share Units on August 19, 2026. This resulted in the acquisition of common shares and a simultaneous disposition of 4,191 common shares to the company for $8.94 per share. Additionally, Dobbs received a new grant of 16,848 Restricted Stock Units on August 17, 2026, which will vest on its first anniversary.
Viemed Healthcare (NASDAQ: VMD) director granted 12,174 RSUs
Viemed Healthcare director Timothy Smokoff reported several equity compensation events, including the vesting and settlement of previously granted Restricted Stock Units (RSUs) and Phantom Share Units, leading to 3,757 common shares being returned to the company at $8.94 per share. Concurrently, he received new grants of 12,174 RSUs and 3,043 Phantom Share Units, set to vest on their first anniversary. These transactions were not conducted under a Rule 10b5-1 trading plan.
209,066 Shares in Viemed Healthcare, Inc. $VMD Acquired by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC recently acquired 209,066 shares of Viemed Healthcare, Inc. (NASDAQ:VMD) worth approximately $2.38 million, representing 0.55% of the company. Institutional investors now own 74.24% of VMD stock. Viemed Healthcare's latest earnings report showed quarterly revenue in line with estimates but missed EPS expectations, and the stock currently holds an average "Hold" rating from analysts.
GSA Capital Partners LLP Invests $1.46 Million in Viemed Healthcare, Inc. $VMD
GSA Capital Partners LLP recently acquired a new stake of 127,591 shares, valued at approximately $1.46 million, in Viemed Healthcare, Inc. Institutional investors collectively own 74.24% of the company, with several other hedge funds also adjusting their positions. Despite exceeding revenue estimates, Viemed Healthcare missed EPS forecasts, and analyst ratings are predominantly "Hold" with some recent downgrades.
Viemed Healthcare (NASDAQ:VMD) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen has downgraded Viemed Healthcare (NASDAQ:VMD) from a "strong buy" to a "buy" rating, with the broader analyst consensus remaining a "hold." This follows Freedom Capital also lowering its rating. The company recently reported quarterly EPS of $0.07, missing the $0.12 consensus, though revenue of $78.1 million slightly exceeded expectations.
(VMD) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis for Viemed Healthcare Inc. (VMD), highlighting weak near and mid-term sentiment but a strong long-term outlook. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes risk management and offers real-time signals and multi-timeframe insights for traders.
Viemed Healthcare, Inc. Revenue Breakdown – NASDAQ:VMD
Viemed Healthcare, Inc. (NASDAQ: VMD) generated $270.28 million USD in revenue last year. The majority of this revenue, $136.75 million USD, came from its Ventilator Rentals, Non-invasive and Invasive segment, an increase from $124.58 million USD in the previous year. All of the company's reported revenue came from the United States.
Viemed (VMD) Q2 2026 Earnings Call Transcript
Viemed Healthcare reported record Q2 2026 revenue of $78.1 million, a 24% year-over-year increase, driven by record ventilator patient counts and growth in sleep therapy and maternal health. The company also announced an all-time high of 12,635 active ventilator patients and significant expansion in other service lines. Despite a dip in adjusted EBITDA margin due to non-recurring gains in the prior year and temporary integration costs, Viemed raised its full-year revenue guidance and lowered its capital expenditure outlook, emphasizing a shift towards less capital-intensive product and service revenue.
Why Viemed Healthcare's (NASDAQ:VMD) Earnings Are Better Than They Seem
Viemed Healthcare's recent earnings, despite seemingly weak stock performance, are better than they appear due to strong cash conversion. The company recorded a negative accrual ratio of -0.11, indicating its free cash flow of US$29m significantly exceeded its statutory profit of US$14.5m. Additionally, unusual items totaling US$2.9m reduced its profit, suggesting that future earnings could improve if these non-recurring expenses do not repeat.
Viemed Healthcare (NASDAQ:VMD) Stock Rating Lowered by Freedom Capital
Freedom Capital downgraded Viemed Healthcare (NASDAQ:VMD) from a "strong buy" to a "hold" rating, while Weiss Ratings simultaneously upgraded it to a "buy." Despite the conflicting ratings, MarketBeat's consensus remains "Hold." The company recently reported Q2 EPS of $0.07, missing analyst estimates, but revenue of $78.1 million slightly exceeded expectations.
Viemed Healthcare | 144: Notice of proposed sale of securities pursuant to Rule 144
This article announces a Form 144 filing by Viemed Healthcare, indicating a proposed sale of securities. The notice is made pursuant to Rule 144 of the Securities Act of 1933, which permits the public resale of restricted and controlled securities if certain conditions are met.
Viemed Healthcare (VMD) Stock Price Sinks As Margin Pressure Clouds Growth
Viemed Healthcare's stock (VMD) dropped almost 16% despite increased Q2 2026 revenue, as net income and profit margins declined year-over-year. The market is reacting to margin pressure, with trailing net profit margin falling to 4.8% from 5.8%, raising questions about whether diversification efforts are effectively boosting profitability. Both bull and bear cases are discussed, highlighting the challenge of turning top-line growth into healthier margins amid cost and mix pressures.
Viemed Healthcare, Inc. $VMD Shares Bought by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership significantly increased its stake in Viemed Healthcare (NASDAQ:VMD) by 101.9% in the first quarter, now owning 1.85% of the company. Other institutional investors like Invesco and Martingale Asset Management also boosted their holdings. Despite beating revenue estimates, Viemed Healthcare missed EPS expectations and analysts currently maintain a "Hold" rating on the stock.
Viemed Healthcare, Inc. (VMD) Stock Price, News, Quote & History
This page provides a comprehensive overview of Viemed Healthcare, Inc. (VMD) stock, including its current price, recent news headlines, and historical performance data. The stock closed at $9.73 on August 7 and has shown positive year-to-date and one-year returns, outperforming the S&P 500 in those periods. Recent news highlights include Q2 2026 earnings call details and estimates, alongside articles discussing insider ownership and growth potential.
Viemed Healthcare Down Over 17%, On Track for Largest Percent Decrease Since January 2019 -- Data Talk
Viemed Healthcare (VMD) stock is experiencing a significant downturn, falling over 17% in intraday trading. This puts the company on track for its largest percentage decrease since January 2019, reflecting a notable negative movement in its share price.
Viemed Healthcare Misses Q2 2026 EPS by 41.7%, Surging Revenue
Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 diluted earnings of $0.07 per share, significantly missing the $0.12 consensus estimate by 41.7%. Despite this, the company saw strong revenue growth, with $78.1 million representing a 23.9% increase year-over-year. The shortfall in earnings, alongside operational expansion serving 12,635 ventilator patients, suggests margin pressures are impacting profitability, though the stock remained largely unchanged.
Earnings call transcript: Viemed Healthcare Q2 2026 profit miss sends shares down 17%
Viemed Healthcare reported mixed Q2 2026 results, with revenue slightly exceeding estimates but earnings falling short, causing a 17% stock drop. The company achieved record revenue of $78.1 million and its highest-ever active ventilator patients, driven by growth across its ventilator, sleep, resupply, and maternal health businesses. Despite strong revenue growth and raised full-year revenue guidance, the profit miss and adjusted EBITDA margin pressure, due to increased operating costs and a shift towards less capital-intensive services, led to investor concern.
Viemed Healthcare Q2 2026 Earnings Call Transcript
Viemed Healthcare reported record Q2 2026 performance with revenue up 24% year-over-year to $78.1 million and a record 12,635 active ventilator patients. The company also saw significant growth in sleep therapy, resupply, and maternal health services, prompting a raised full-year revenue guidance to $314 million-$320 million. Despite a lowered adjusted EBITDA guidance due to investments and growth in lower-margin services, Viemed repurchased shares and maintains a strong financial foundation for continued expansion and productivity gains.
Does Viemed Healthcare Inc (VMD) Justify Its 6.2% Overvaluation
Viemed Healthcare Inc (VMD) reported strong Q2 2026 financial results with net revenues of $78.1 million, a 23.9% increase year-over-year, and significant growth in patient numbers for ventilator and PAP therapy. Despite this growth, net income and Adjusted EBITDA saw declines, and the stock is currently estimated to be 6.2% overvalued according to GuruFocus, with insider selling indicating caution. The company maintains a strong financial position but faces challenges in maintaining profitability amidst rapid expansion.
Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates
Viemed Healthcare, Inc. (VMD) reported Q2 earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.10. Despite this earnings miss, the company's revenues of $78.1 million surpassed estimates and showed growth from the prior year. The stock has outperformed the S&P 500 year-to-date, and its current Zacks Rank is #3 (Hold), indicating an expected performance in line with the market.
